Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 8/20 | 0.48 |
| ▸ | HCK | P08631 | 7/20 | 0.48 |
| ▸ | MAPK12 | P53778 | 6/20 | 0.48 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.45 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.45 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.39 |
| ▸ | CTSV | O60911 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1978082 | 1.00 | MAPK14 (0.48) | MAPK14HCKMAPK12POLBNPC1 | |
| SCHEMBL2572968 | 0.92 | HCK (0.52) | MAPK14HCKMAPK12POLBNPC1 | |
| SCHEMBL2405629 | 0.87 | MAPK14 (0.48) | MAPK14HCKMAPK12POLBNPC1 | |
| SCHEMBL2548864 | 0.85 | HCK (0.43) | MAPK14HCKMAPK12POLBNPC1 | |
| SCHEMBL2309465 | 0.84 | POLB (0.45) | MAPK14HCKMAPK12POLBNPC1 | |
| SCHEMBL2309475 | 0.84 | POLB (0.45) | MAPK14HCKMAPK12POLBNPC1 | |
| SCHEMBL1979137 | 0.84 | NR3C2 (0.51) | MAPK14HCKMAPK12NR3C2TNF | |
| SCHEMBL1981083 | 0.83 | POLB (0.46) | POLBNPC1RAB9ASMN1; SMN2NR3C2 | |
| SCHEMBL1981080 | 0.83 | POLB (0.46) | POLBNPC1RAB9ASMN1; SMN2NR3C2 | |
| SCHEMBL13331035 | 0.81 | SMN1; SMN2 (0.46) | MAPK14HCKMAPK12POLBNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2370428-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2016-08-10 | — | — | EP | disclosed |
| US-8975285-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2015-03-10 | — | — | US | disclosed |
| US-20140114064-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2014-04-24 | — | — | US | disclosed |
| EP-2350049-B1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD (GB) | 2014-02-26 | — | — | EP | disclosed |
| US-8618140-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD (GB) | 2013-12-31 | — | — | US | disclosed |
| EP-2556067-A2 | PYRAZOLYL UREAS AS P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2013-02-13 | — | — | EP | disclosed |
| US-20130012512-A1 | P38 MAP kinase inhibitors | ITO KAZUHIRO (GB) | 2013-01-10 | — | — | US | disclosed |
| US-8299073-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-30 | — | — | US | disclosed |
| US-8293748-B2 | p38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2012-10-23 | — | — | US | disclosed |
| EP-2509595-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | Respivert Limited (GB) | 2012-10-17 | — | — | EP | disclosed |
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-12-01 | — | — | US | disclosed |
| WO-2011124923-A2 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-10-13 | — | — | WO | disclosed |
| EP-2370428-A1 | P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2011-10-05 | — | — | EP | disclosed |
| US-20110212962-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LTD. (GB) | 2011-09-01 | — | — | US | disclosed |
| EP-2350049-A2 | P38 MAP KINASE INHIBITORS | Respivert Limited (GB) | 2011-08-03 | — | — | EP | disclosed |
| WO-2011070368-A1 | ANTIVIRAL USE OF UREA COMPOUNDS | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011070369-A1 | INHIBITORS OF HEMOPOIETIC CELL KINASE (P59-HCK) AND THEIR USE IN THE TREATMENT OF INFLUENZA INFECTION | RESPIVERT LIMITED (GB) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010067131-A1 | P38 MAP KINASE INHIBITORS | RESPIVERT LIMITED (GB) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010038086-A2 | NOVEL COMPOUNDS | RESPIVERT LIMITED (GB) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294812-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAP3K1, MAPK3 | MAPK14 10/4885HCK 348/4885MAPK12 13/4885 |
| US-20130012512-A1 | P38 MAP kinase inhibitors | MAPK1, MAPK3, MAPK6 | MAPK14 33/4885HCK 2830/4885MAPK12 31/4885 |
| US-20110212962-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAPK3, MAPK6 | MAPK14 33/4885HCK 2830/4885MAPK12 31/4885 |
| US-20140114064-A1 | P38 MAP KINASE INHIBITORS | MAPK1, MAPK3, MAPK6 | MAPK14 33/4885HCK 2830/4885MAPK12 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.